Effects of levetiracetam on chronic pain in multiple sclerosis: Results of a pilot, randomized, placebo-controlled study

European Journal of Neurology

Volumn 16, Issue 3, 2009, Pages 360-366

  Rossi, S ^a,b   Mataluni, G ^a,b   Codeca C ^a,b   Fiore, S ^a,b   Buttari, F ^a,b   Musella, A ^a,b   Castelli, M ^a,b   Bernardi, G ^a,b   Centonze, D ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Anticonvulsants; Chronic neuropathic pain; Clinical trial; Levetiracetam; Multiple sclerosis; Pain

Indexed keywords

ETIRACETAM; PLACEBO;

ADULT; ARTICLE; BODY TEMPERATURE DISORDER; BONE MARROW TOXICITY; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DISABILITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFLUENZA; INSOMNIA; LIVER TOXICITY; MALE; MULTIPLE SCLEROSIS; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; OPTIMAL DRUG DOSE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SORE THROAT; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; VITAL SIGN; WEIGHT CHANGE;

ADULT; ANALGESICS; ANTICONVULSANTS; DEPRESSION; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEURALGIA; PAIN MEASUREMENT; PILOT PROJECTS; PIRACETAM; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60049101455     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02496.x     Document Type: Article

References (42)

1. Ehde DM, Gibbons LE, Chwastiak L, Bombardier CH, Sullivan MD, Kraft GH. Chronic pain in a large community sample of persons with multiple sclerosis. Multiple Sclerosis 2003 9 : 605 611.
2. Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. Archives of Neurology 2003 60 : 1089 1094.
3. Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004 63 : 919 921.
4. Khan F, Pallant J. Chronic pain in multiple sclerosis: prevalence, characteristics, and impact on quality of life in an Australian community cohort. Journal of Pain 2008 8 : 614 623.
5. O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008 137 : 96 111.
6. Wang HM, Beyer M, Gensichen J, Gerlach FM. Health-related quality of life among general practice patients with differing chronic diseases in Germany: cross sectional survey. BMC Public Health 2008 8 : 246.
7. Stewart ST, Woodward RM, Rosen AB, Cutler DM. The impact of symptoms and impairments on overall health in US national health data. Medical Care 2008 46 : 954 962.
8. Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain 2007 127 : 35 41.
9. Kenner M, Menon U, Elliott DG. Multiple sclerosis as a painful disease. International Review of Neurobiology 2007 79 : 303 321.
10. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis - prevalence and clinical characteristics. European Journal of Pain 2005 9 : 531 542.
11. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005 65 : 812 819.
12. Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clinical Therapeutics 2007 29 : 2022 2030.
13. Solaro C, Tanganelli P, Messmer Uccelli M. Pharmacological treatment of pain in multiple sclerosis. Expert Review of Neurotherapeutics 2007 7 : 1165 1174.
14. Ardid D, Lamberty Y, Alloui A, Coudore-Civiale MA, Klitgaard H, Eschalier A. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. European Journal of Pharmacology 2003 473 : 27 33.
15. Archer DP, Lamberty Y, Wang B, Davis MJ, Samanani N, Roth SH. Levetiracetam reduces anesthetic-induced hyperalgesia in rats. Anesthesia and Analgesia 2007 104 : 180 185.
16. Guay DR. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. American Journal of Geriatric Pharmacotherapy 2003 1 : 18 37.
17. Rowbotham MC, Manville NS, Ren J. Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia. Neurology 2003 61 : 866 867.
18. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clinical Journal of Pain 2004 20 : 33 36.
19. Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. European Journal of Pain 2006 10 : 193 198.
20. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001 50 : 121 127.
21. Indaco A, Iachetta C, Nappi C, Socci L, Carrieri PB. Chronic and acute pain syndromes in patients with multiple sclerosis. Acta Neurologica 1994 16 : 97 102.
22. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurologica Scandinavica 1991 84 : 197 200.
23. Ehde DM, Osborne TL, Hanley MA, Jensen MP, Kraft GH. The scope and nature of pain in persons with multiple sclerosis. Multiple Sclerosis 2006 12 : 629 638.
24. Beiske AG, Pedersen ED, Czujko B, Myhr KM. Pain and sensory complaints in multiple sclerosis. European Journal of Neurology 2004 11 : 479 482.
25. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983 33 : 1444 1452.
26. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967 6 : 278 296.
27. Solari A, Filippini G, Mendozzi L, et al. Validation of Italian multiple sclerosis quality of life 54 questionnaire. Neurol Neurosurg Psychiatry 1999 67 : 158 162.
28. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001 94 : 149 158.
29. Warke K, Al-Smadi J, Baxter D, Walsh DM, Lowe-Strong AS. Efficacy of transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain in a multiple sclerosis population. A randomized, placebo-controlled clinical trial. Clinical Journal of Pain 2006 22 : 812 819.
30. Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clinical Neuropharmacology 2006 29 : 338 342.
31. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000 41 : 1276 1283.
32. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. Journal of Neuro-Oncology 2006 78 : 99 102.
33. Striano P, Coppola A, Vacca G, et al. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. Journal of Neurology 2006 253 : 762 766.
34. Sakurai M, Mannen T, Kanazawa I, Tanabe H. Lidocaine unmasks silent demyelinative lesions in multiple sclerosis. Neurology 1992 42 : 2088 2093.
35. + currents. Seizure 2001 10 : 279 286.
36. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels. Epilepsia 2002 43 : 9 18.
37. 2+ transient and epileptiform potentials in hippocampal neurons. Neuropharmacol Neurotoxicol 2003 3 : 471 475.
38. Löscher W, Hönack D, Bloms-Funke P. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Research 1996 735 : 208 216.
39. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neural GABA- and glycine-gated currents. British Journal of Pharmacology 2002 136 : 659 672.
40. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 2004 26 : 9861 9866.
41. Salter MW. Cellular neuroplasticity mechanisms mediating pain persistence. Journal of Orofacial Pain 2004 18 : 318 324.
42. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. Journal of Neuroscience 2003 23 : 2899 2910.